Afreen Shariff, MD, MBBS, Duke Cancer Institute, discusses the challenges and benefits of electronic consults (e-consults) for patients with cancer currently undergoing treatment who have a comorbidity history or who develop an endocrine system disorder because of treatment.
At the recent Association of Community Cancer Centers’ 40th National Oncology Conference, held October 4-6 in Austin, Texas, Afreen Shariff, MD, MBBS, director at Duke Endo-Oncology Program, Duke Endocrinology, Duke Cancer Institute, sat down for a conversation with The American Journal of Managed Care® to discuss both the challenges and benefits of electronic consults (e-consults) for patients with cancer currently undergoing treatment who have a comorbidity history or who develop an endocrine system disorder because of treatment.
Here she discusses for whom and in what conditions e-consults are a potential mode of care access.
Transcript
Are there specific patient populations or medical conditions in which e-consults can be particularly beneficial?
I think any area within cancer care can be transformed through e-consults, whether it is psychiatry, psychology care. I think the more niche you are in practice—in the sense that if it is a cardiologist that specializes in cancer therapies and cancer care, or if it is a nephrologist that specializes in cancer therapies and kind of cancer toxicities—depending on what the needs are of the practice, really, defining that and matching that with the experts around the country is where electronic consults can be very helpful. Anywhere where you identify poor access is an opportunity where electronic consults can be very well utilized.
Disparities in Telehealth Access Undermine Adoption Among Patients With Schizophrenia
January 16th 2025The COVID-19 pandemic accelerated the widespread adoption of telemental health care, and new research indicates significant racial and ethnic disparities in access to this technology among Medicaid beneficiaries with schizophrenia.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen